The single-dose Janssen Ad26.COV2.S COVID-19 vaccine elicited robust and persistent anti-spike IgG antibody responses in a 12-month Ugandan cohort

IntroductionThe study investigation examined the immune response to the Janssen Ad26.COV2.S COVID-19 vaccine within a Ugandan cohort, specifically targeting antibodies directed against spike (S) and nucleocapsid (N) proteins. We aimed to examine the durability and robustness of the induced antibody...

Descripción completa

Detalles Bibliográficos

Autores principales:	Jennifer Serwanga, Laban Kato, Gerald Kevin Oluka, Violet Ankunda, Jackson Sembera, Claire Baine, Isaac Kitabye, Angela Namuyanja, Solomon Opio, Joseph Ssebwana Katende, Peter Ejou, The COVID-19 Immunoprofiling Team, Pontiano Kaleebu
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Frontiers Media S.A. 2024-05-01
Colección:	Frontiers in Immunology
Materias:	Janssen Ad26.COV2.S vaccine SARS-CoV-2 immunity spike protein antibodies nucleocapsid protein antibodies Ugandan vaccine cohort single-dose vaccination
Acceso en línea:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1384668/full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!